The companies named in the program include a pan-European mix of startup initiatives and university research projects. The selected companies are as follows:

• Flash Diagnostics, which is developing microscopy technology for use in the clinical diagnosis of cancer patients
• Stimuliver, which is developing a "disruptive" liver implant that can treat critically failing liver function in humans
• Commit Biologics, a spinout from Aarhus University that is utilizing B-specific domain antibodies to target a variety of cancers
• HEI Therapeutics, a digital therapeutics company that has a medical-grade home monitoring system for thyroid conditions
• NewOstomyLife, which has developed new technology for collecting output from ostomies
• EvodiaBio, a bioindustrial company that produces sustainable, natural aromas for the food and beverage industry
• Bioomix, which develops microbial technology to replace fungicides, synthetic fertilizers, and antibiotics

The 12-month Venture Lab program is designed to help propel research-based ideas with high-growth commercial potential into viable startup companies, according to the Denmark-based institute.

Besides being awarded a risk-free convertible loan of 500,000 euros ($590,400 U.S.), the seven ventures will receive scientific and team development support and will gain access to BII labs and offices located in Copenhagen.

New award program recognizes marketable scientific advances
A new award to recognize researchers who ask fundamental questions at the intersection of life sciences and entrepreneurship has been launched by the...

BioInnovation Institute thrives in Denmark
The Novo Nordisk Foundation has established the BioInnovation Institute as an independent foundation and will provide up to 470 million euros ($570 million...